Differential effects of subcutaneous and sublingual immunotherapy on timothy grass-specific T H 2 CD4 + T-cell subsets.
Hannah A DeBerg, Carolyn H Baloh, Quinn DeGottardi et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, double-blind, placebo-controlled trial examined timothy grass-specific CD4+ T-cell subsets in longitudinal blood samples from participants receiving sublingual immunotherapy (SLIT) or subcutaneous immunotherapy (SCIT). The cells formed two major phenotypic groups: CRTH2hi CD27lo and CRTH2lo CD27hi. SCIT preferentially depleted the former subset, whereas SLIT depleted the latter, indicating different but potentially overlapping immunologic effects. Frequencies in both subsets showed weak positive correlations with Total Nasal Symptom Score; CRTH2hi CD27lo frequency also correlated with grass-specific IgE and IgG4, but not IgA.
Key findings
- SCIT preferentially depleted CRTH2hi CD27lo timothy grass-specific CD4+ T cells.
- SLIT preferentially depleted CRTH2lo CD27hi timothy grass-specific CD4+ T cells.
- Frequencies in both T-cell subsets showed weak positive correlations with Total Nasal Symptom Score.
- CRTH2hi CD27lo cell frequency correlated with Phl p-specific IgE and IgG4, but not IgA.
Why it matters
The findings show that allergen-specific CD4+ T cells comprise distinct subsets and that the two immunotherapy routes do not affect them identically. This provides a more detailed view of possible immune pathways associated with SLIT and SCIT and may help inform research into how cellular responses relate to symptoms and allergen-specific antibodies.
What to keep in mind
The abstract reports cellular and correlation findings but does not provide quantitative effect estimates or establish that the observed T-cell changes cause clinical improvement.